Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D7YR
|
||||
| Former ID |
DIB002277
|
||||
| Drug Name |
AMPE4L
|
||||
| Synonyms |
Exendin4-Fc-Leptin; GLP1-Fc-Leptin; Exendin4-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
|
||||
| Company |
AmProtein Corp
|
||||
| Target and Pathway | |||||
| Target(s) | Glucagon-like peptide 1 receptor | Target Info | Modulator | [530376], [532841], [551186] | |
| Leptin receptor | Target Info | Modulator | [543464] | ||
| Pathway Interaction Database | Signaling events mediated by PTP1B | ||||
| References | |||||
| Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
| Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | ||||
| Ref 551186 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | ||||
| Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
| Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | ||||
| Ref 543464 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). | ||||
| Ref 551186 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.